Gideon Michael Blumenthal

16.8k citations
110 papers · 13.0k · 3 hit papers · h-index 52

Impact in

  • Cancer Research top 0.5%
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research

Papers in

  • Oncology 49
    • Cancer Immunotherapy and Biomarkers 20
    • CAR-T cell therapy research 7
    • HER2/EGFR in Cancer Research 7
    • Colorectal Cancer Treatments and Studies 7
  • Cancer Research 23
    • Cancer Genomics and Diagnostics 20
Co-authors
Richard M. Pazdur (65 shared papers)Phillip A. Dennis (8 shared papers)Patricia A. Keegan (26 shared papers)Mary Christine Hollander (1 shared paper)Kun He (10 shared papers)Dickran Gano Kazandjian (14 shared papers)Kirsten B. Goldberg (20 shared papers)Wendy B. Bernstein (2 shared papers)
Journals
Clinical Cancer Research (22 papers)The Oncologist (22 papers)JAMA Oncology (11 papers)Clinical Pharmacology & Therapeutics (8 papers)Journal of Thoracic Oncology (5 papers)
Partner nations
United StatesChinaThailand

In The Last Decade

Gideon Michael Blumenthal

108 papers receiving 12.7k citations

Gideon Michael Blumenthal's Hit Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis 2014 · 3.6k citations
3.6k0+6+12Years since publication10002.0k3.0k
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2014 The Lancet
  2. 2011 Nature reviews. Cancer
  3. 2008 Drug Resistance Updates

Peers

Gideon Michael Blumenthal
Comparison fields: 5 of 148
  • Cancer Research 3.4k
  • Oncology 5.4k
  • Pulmonary and Respiratory Medicine 2.9k
  • Pathology and Forensic Medicine 923
  • Immunology 1.1k
Replace Shenghui W. Tang with:
Shenghui W. Tang United States
Christophe Le Tourneau France
Shivaani Kummar United States
Alberto Ocaña Spain
Robert L. Justice United States
Edward S. Kim United States
Anthony Gonçalvès France
David Olmos Hidalgo Spain
Minetta C. Liu United States
P. Fumoleau France
Gideon Michael Blumenthal relative to Shenghui W. Tang United States Shenghui W. Tang's profile →
Citations per field
00.5×1.6×
Shenghui W. Tang · 1×
Citations per year

Countries citing papers authored by Gideon Michael Blumenthal

Since Specialization
Citations

This map shows the geographic impact of Gideon Michael Blumenthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gideon Michael Blumenthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gideon Michael Blumenthal more than expected).

Fields of papers citing papers by Gideon Michael Blumenthal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gideon Michael Blumenthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gideon Michael Blumenthal. The network helps show where Gideon Michael Blumenthal may publish in the future.

Co-authors

The 25 scholars most cited alongside Gideon Michael Blumenthal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gideon Michael Blumenthal Line = papers co-authored together Gideon Michael Blumenthal links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet ·Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur M. Mehta, Joseph P. Costantino, Norman Wolmark, Herve R. Bonnefoi, David Cameron
Hit paper breakdown →		20143645
2
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Drug Resistance Updates ·Jaclyn LoPiccolo, Gideon Michael Blumenthal, Wendy B. Bernstein, Phillip A. Dennis
Hit paper breakdown →		2008691
3
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Nature reviews. Cancer ·Mary Christine Hollander, Gideon Michael Blumenthal, Phillip A. Dennis
Hit paper breakdown →		2011679
4
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
The Oncologist ·Dickran Gano Kazandjian, Daniel L. Suzman, Gideon Michael Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia A. Keegan, Richard M. Pazdur
2016366
5
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
The Oncologist ·Joohee Sul, Gideon Michael Blumenthal, Xiaoping Jiang, Kun He, Patricia A. Keegan, Richard M. Pazdur
2016313
6
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research ·Laleh Amiri‐Kordestani, Gideon Michael Blumenthal, Qiang Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi
2014300
7
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Clinical Cancer Research ·Aviva C. Krauss, Xin Gao, Liang Li, Michael L. Manning, Paresma Patel, Wentao Fu, Kumar Gaurav Janoria, Gerlie Gieser
2018281
8
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
The Oncologist ·Lee H. Pai-Scherf, Gideon Michael Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi Shruti Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu
2017251
9
Real-world Data for Clinical Evidence Generation in Oncology
JNCI Journal of the National Cancer Institute ·Sean Khozin, Gideon Michael Blumenthal, Richard M. Pazdur
2017250
10
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics
JAMA Oncology ·Julia A. Beaver, Lynn Jackson Howie, Lorraine Cheryl Pelosof, Tamy Kim, Jinzhong Liu, Kirsten B. Goldberg, Rajeshwari Sridhara, Gideon Michael Blumenthal
2018246
11
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
The Oncologist ·Dickran Gano Kazandjian, Gideon Michael Blumenthal, Huanyu Chen, Kun He, Mona Patel, Robert L. Justice, Patricia A. Keegan, Richard M. Pazdur
2014245
12
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
The Lancet Oncology ·Jennifer J. Gao, Joyce Cheng, Erik W. Bloomquist, Jacquelyn Sanchez, Suparna Bonthala Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim
2019235
13
PTEN hamartoma tumor syndromes
European Journal of Human Genetics ·Gideon Michael Blumenthal, Phillip A. Dennis
2008234
14
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Clinical Cancer Research ·Najat Bouchkouj, Yvette L. Kasamon, Romeo Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon Michael Blumenthal, Wilson W. Bryan
2018207
15
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
Clinical Cancer Research ·Dickran Gano Kazandjian, Gideon Michael Blumenthal, Weishi Yuan, Kun He, Patricia A. Keegan, Richard M. Pazdur
2016200
16
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Clinical Cancer Research ·Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Mary Weber Redman, Michael Leo LeBlanc, Philip C. Mack, Lawrence Howard Schwartz, Everett E. Vokes
2015193
17
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
The Oncologist ·Lauretta Odogwu, Luckson Noe Mathieu, Gideon Michael Blumenthal, Erin A. Larkins, Kirsten B. Goldberg, Norma Sue Griffin, Karen E. Bijwaard, Eunice Y. Lee
2018188
18
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
The Oncologist ·Erin A. Larkins, Gideon Michael Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu
2017184
19
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Journal of Clinical Oncology ·Gideon Michael Blumenthal, Stella Wanjugu Karuri, Hui Zhang, Lijun Zhang, Sean Khozin, Dickran Gano Kazandjian, Shenghui W. Tang, Rajeshwari Sridhara
2015181
20
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer
JAMA Oncology ·Dickran Gano Kazandjian, Yutao U. T. Gong, Patricia A. Keegan, Richard M. Pazdur, Gideon Michael Blumenthal
2019166

About Gideon Michael Blumenthal

Gideon Michael Blumenthal is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Statistics and Probability and Hematology, having authored 110 papers that have together received 13.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (20 papers), Cancer Immunotherapy and Biomarkers (20 papers), Statistical Methods in Clinical Trials (12 papers), Advanced Breast Cancer Therapies (9 papers), CAR-T cell therapy research (7 papers), HER2/EGFR in Cancer Research (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). The work is most often cited by research in Cancer Research (3.4k citations), Oncology (5.4k citations), Pulmonary and Respiratory Medicine (2.9k citations), Pathology and Forensic Medicine (923 citations) and Immunology (1.1k citations). Gideon Michael Blumenthal has collaborated with scholars based in United States, China and Thailand. Frequent co-authors include Richard M. Pazdur, Phillip A. Dennis, Patricia A. Keegan, Mary Christine Hollander, Kun He, Dickran Gano Kazandjian, Kirsten B. Goldberg, Wendy B. Bernstein, Jaclyn LoPiccolo and Sean Khozin. Their work appears in journals such as Clinical Cancer Research, The Oncologist, JAMA Oncology, Clinical Pharmacology & Therapeutics and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shenghui W. TangBreakdown of academic impact, for papers by Christophe Le TourneauBreakdown of academic impact, for papers by Shivaani KummarBreakdown of academic impact, for papers by Alberto OcañaBreakdown of academic impact, for papers by Robert L. JusticeBreakdown of academic impact, for papers by Edward S. KimBreakdown of academic impact, for papers by Anthony GonçalvèsBreakdown of academic impact, for papers by David Olmos HidalgoBreakdown of academic impact, for papers by Minetta C. LiuBreakdown of academic impact, for papers by P. Fumoleau